IL2 and cancer: The systemic inflammatory response from cancer cells promotes the infiltration of neutrophils, which benefits cancer progression via the secretion of interleukin (IL)‐2, IL‐6, IL‐10, tumor necrosis factor α (TNF‐α), and vascular endothelial growth factor (VEGF).13